Rebecca is an experienced pricing and market access (PMA) professional with almost a decade of experience focused on the value of therapeutics. She has global expertise, having lived and worked in both the EU and US during her consulting career. Her projects focus on pricing and market access in all guises, including asset valuation, evidence generation to support reimbursement, value-based pricing, PMA strategy (from Phase I to launch and lifecycle), and US and EU commercialization strategy.
Prior to joining CRA, Rebecca was a Principal at ICON Commercialisation and Outcomes, having joined the team through the acquisition of PriceSpective where she worked from 2010.
Rebecca has written articles for various publications, latterly with a focus on cell and gene therapies.
MSc, Clinical Research, Cranfield University
BA and MA, Oxon Physiology and Psychology, University of Oxford